Girish Venkataraman to Mutation
This is a "connection" page, showing publications Girish Venkataraman has written about Mutation.
Connection Strength
1.645
-
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
Score: 0.407
-
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms. Br J Haematol. 2025 Apr; 206(4):1103-1108.
Score: 0.386
-
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
Score: 0.375
-
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
Score: 0.104
-
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
Score: 0.102
-
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
Score: 0.093
-
Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators. Haematologica. 2022 04 01; 107(4):966-969.
Score: 0.080
-
Erythroblastic Sarcoma in Adults and Children: Different Pathways to the Same Destination. Mod Pathol. 2025 Aug; 38(8):100716.
Score: 0.025
-
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms. Blood Adv. 2024 11 26; 8(22):5796-5805.
Score: 0.024
-
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020 08; 59(8):484-494.
Score: 0.018
-
Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. Leukemia. 2020 08; 34(8):2238-2242.
Score: 0.017
-
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
Score: 0.014